OncoMatch/Clinical Trials/NCT06752798
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
Is NCT06752798 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Trilaciclib + Cisplatin for head and neck cancer squamous cell carcinoma.
Treatment: Trilaciclib + Cisplatin — To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as an adjuvant treatment for Head and neck cancer after surgery
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T1-4N0-3M0, PT3-4, PN2-3
Staging of T1-4N0-3M0, having undergone radical surgery; ... postoperative pathological staging pT3-4 or pN2-3
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Previous chemotherapy for any reason
Cannot have received: surgery
Exception: prior surgery in the head and neck region allowed only if radical surgery for current diagnosis
prior surgery ... in the head and neck region
Cannot have received: radiotherapy
Exception: postoperative radiotherapy for current diagnosis allowed
prior ... radiotherapy ... in the head and neck region
Cannot have received: molecular targeted therapy
prior ... molecular targeted therapy ... in the head and neck region
Cannot have received: immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, anti-PD-L2)
prior ... immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, anti-PD-L2, etc.) in the head and neck region
Cannot have received: hematopoietic stem cell or bone marrow transplant
Previous hematopoietic stem cell or bone marrow transplant
Lab requirements
Blood counts
HB ≥ 90 g/L; Neu ≥ 1.5×10^9/L; PLT ≥ 100×10^9/L; no blood transfusion or blood products within 14 days
Kidney function
Serum Cr ≤ 1.0× ULN or creatinine clearance rate > 60 ml/min
Liver function
TBIL < 1.5× ULN; ALT and AST < 2.5× ULN
Cardiac function
No Grade I or higher myocardial ischemia or myocardial infarction, arrhythmia, or Grade II heart failure; no stroke or cardiovascular events within 6 months prior to enrollment
Normal major organ function, meeting the following criteria: ... Hematology standards ... Biochemical criteria ... Abnormal function of vital organs such as the heart, brain, or lungs: Hypertension that cannot be controlled ... myocardial ischemia or myocardial infarction, arrhythmia, and Grade II heart failure; stroke or cardiovascular events within 6 months prior to enrollment; abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with a tendency to bleed or receiving thrombolytic or anticoagulant therapy; clear tendency to bleed; patients with positive proteinuria (urine protein test 2+ or above, or 24-hour urine protein quantification > 1.0 g).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06752798 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1-4N0-3M0 or PT3-4 or PN2-3 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages